STRO vs RCUS vs BOLT vs NKTR vs AGIO

For growth investors, Agios Pharmaceuticals, Inc.

(AGIO) is the stronger pick with 48. 0% revenue growth year-over-year, versus -59. 6% for Sutro Biopharma, Inc. (STRO). Analysts rate Sutro Biopharma, Inc. (STRO) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Sutro Biopharma, Inc.

(STRO) delivered a total return of +106. 5%, compared to -99. 0% for Bolt Biotherapeutics, Inc. (BOLT). Over 10 years, the gap is even starker: STRO returned +162. 0% versus BOLT's -99. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bolt Biotherapeutics, Inc.

(BOLT) is the lower-risk stock at 1. 01β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 92% more volatile than BOLT relative to the S&P 500. On balance sheet safety, Agios Pharmaceuticals, Inc. (AGIO) carries a lower debt/equity ratio of 5% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Agios Pharmaceuticals, Inc.

(AGIO) is pulling ahead at 48. 0% versus -59. 6% for Sutro Biopharma, Inc. (STRO). On earnings-per-share growth, the picture is similar: Arcus Biosciences, Inc. grew EPS -4. 8% year-over-year, compared to -981. 8% for Bolt Biotherapeutics, Inc.. Over a 3-year CAGR, AGIO leads at 56. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Arcus Biosciences, Inc.

(RCUS) is the more profitable company, earning -142. 9% net margin versus -764. 0% for Agios Pharmaceuticals, Inc. — meaning it keeps -142. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RCUS leads at -156. 3% versus -873. 9% for AGIO. At the gross margin level — before operating expenses — BOLT leads at 103. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Bolt Biotherapeutics, Inc.

(BOLT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 01)). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BOLT: -99. 3%, RCUS: +45. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: STRO is a small-cap quality compounder stock; RCUS is a small-cap quality compounder stock; BOLT is a small-cap quality compounder stock; NKTR is a small-cap quality compounder stock; AGIO is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.